Meeting
2015 ASCO Annual Meeting
A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas.
Authors
Jakub Svoboda
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Jakub Svoboda , Lauren Strelec , Nirav Niranjan Shah , Elise A Chong , Kathleen Montrey , Kristy Walsh , Scott F. Huntington , Anthony Mato , Daniel Jeffrey Landsburg , Sunita Nasta , Stephen J. Schuster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01575860
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8553)
DOI
10.1200/jco.2015.33.15_suppl.8553
Abstract #
8553
Poster Bd #
371
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report.
First Author: Peter D. Cole
Poster
2014 ASCO Annual Meeting
A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results.
First Author: Matthew Alexander Lunning
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens
Poster
2021 ASCO Annual Meeting
High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.
First Author: Adriana C. Rossi